Lannett Co Inc (NYSE:LCI) Analyst Rating Consensus

Lannett Co Inc (NYSE:LCI) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1.6 by 5 Brokerage Firm. 3 Wall Street Firms have rated the stock as a strong buys. 1 stock experts have also suggested a buy rating. 1 Brokerage Firms have advised hold.

Other Equity analysts have also commented on the company shares. Major Brokerage house, Canaccord Genuity downgrades its ratings on Lannett Co Inc (NYSE:LCI). In the latest research report, Canaccord Genuity lowers the target price from $28 per share to $18 per share. According to the latest information available, the shares are now rated Sell by the analysts at the agency. Previously, the analysts had a Buy rating on the shares. The rating by the firm was issued on March 24, 2016.

Lannett Co Inc (NYSE:LCI) shares are expected to touch $31.17 in the short term. This short term price target has been shared by 3 analysts. However, the standard deviation of short term price estimate has been valued at 3.75. The target price could hit $35 on the higher end and $28 on the lower end.

Lannett Co Inc (NYSE:LCI) witnessed a decline in the market cap on Tuesday as its shares dropped 1.13% or 0.28 points. After the session commenced at $24.76, the stock reached the higher end at $24.76 while it hit a low of $23.71. With the volume soaring to 859,612 shares, the last trade was called at $24.47. The company has a 52-week high of $62.9. The company has a market cap of $899 million and there are 36,747,501 shares in outstanding. The 52-week low of the share price is $16.91.

Lannett Company, Inc. has dropped 4.11% in the last five trading days, however, the shares have posted positive gains of 8.76% in the last 4 weeks. Lannett Company, Inc. is up 20.36% in the last 3-month period. Year-to-Date the stock performance stands at -39.01%.

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Companys products include Levothyroxine Sodium tablets, Digoxin tablets, Butalbital products, Ursodiol capsules and pain management products. Levothyroxine Sodium tablets are produced and marketed with around 12 varying potencies. Digoxin tablets are produced and marketed with approximately two different potencies. It distributes around three products containing Butalbital. Ursodiol capsules are produced and marketed in 300 milligram capsules. The Company offers a range of pain management products, such as Cocaine Topical Solution (C-Topical), Morphine Sulfate Oral Solution, Hydromorphone hydrochloric acid (HCl) tablets and Codeine Sulfate tablets.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.